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Introduction
Renal amyloidosis (RA) of Familial Mediterranean Fever
(FMF) – although largely preventable –still is a major
health problem in Armenia and an important cause of
death.
Objectives
The aim of the study is to investigate the long-term out-
come of patients with renal amyloidosis on RRT.
Methods
From January 2002 till September 2012 279 patients were
admitted to our centre for Renal Replacement Therapy
(RRT), of whom 40 (14.3%) had RA of FMF. Their mean
age was 31.4±12.7 (range 12.6–52.9), 60% were males.
Mean duration of hemodialysis (HD) was 1.6±1.7 years
(range 0.1-6.0).
Results
Hemodialysis: Of the 28 patients not undergoing renal
transplantation (Tx) in Armenia, 9 died (systemic amyloi-
dosis - 5, heart attack - 2, stroke -2); 15 moved to another
country and 4 remained on dialysis. Over half of the
25 pts with minimum observation period of 6 mo were
resistant to EPO. One third died, mainly due to cardiovas-
cular complications and systemic amyloidosis.
Living related donor Tx was done after 8 mo (median)
of HD in 12 patients aged 38 ± 11.6 years, i.e. 12.5% of all
Tx (96) done at the same period. In addition to standard
immunosuppression all received low dose colchicine
(0.6-1.2 mg/day). Main complications were rejection (8),
delayed graft function for tubular necrosis (2), lymphocele
(2), CMV disease (2) and tuberculosis (1). Additional pro-
blems included diarrhea (colchicine, MMF, generalized
amyloidosis; 9) and severe neuropathy due to interaction
of cyclosporine with colchicine (1). Interaction of colchi-
cine with CNI/MMF (neuropathy,diarrhea) required
reduction of immunosuppression in some patients, result-
ing in higher rejection rate. One patient died of general-
ized amyloidosis and 1 kidney was lost after reduction of
immunosuppression due to tuberculosis. Ten patients
have good renal function.
Conclusion
The number of patients with amyloidosis of FMF requir-
ing RRT in Armenia is alarming. Prevention of RA by
early diagnosis and early intervention (colchicine) must be
intensified. Outcome of HD was poor in contrast to renal
Tx. Results after renal Tx were much better than for HD
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